Transplantation of autologous extracellular vesicles for cancer-specific targeting

Nano- and microsized extracellular vesicles (EVs) are naturally occurring cargo-bearing packages of regulatory macromolecules, and recent studies are increasingly showing that EVs are responsible for physiological intercellular communication. Nanoparticles encapsulating anti-tumor theranostics represent an attractive “exosome-interfering” strategy for cancer therapy. Methods: Herein, by labeling plasma-derived EVs with indocyanine green (ICG) and following their biodistribution by in vivo and ex vivo imaging, we demonstrate the existence of nanoparticles with a highly selective cancer tropism in the blood of colorectal cancer (CRC) patients but not in that of healthy volunteers. Results: In CRC patient-derived xenograft (PDX) mouse models, we show that transplanted EVs recognize tumors from the cognate nanoparticle-generating individual, suggesting the theranostic potential of autologous EVs encapsulating tumor-interfering molecules. In large canine breeds bearing spontaneous malignant skin and breast tumors, the same autologous EV transplantation protocol shows comparable safety and efficacy profiles. Conclusions: Our data show the existence of an untapped resource of intercellular communication present in the blood of cancer patients, which represents an efficient and highly biocompatible way to deliver molecules directly to the tumor with great precision. The novel EV-interfering approach proposed by our study may become a new research direction in the complex interplay of modern personalized cancer therapy.

[1]  Tanaka,et al.  The role of , 2021, Journal of insect physiology.

[2]  I. Kwon,et al.  Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity , 2020, Science Advances.

[3]  Yan Ling,et al.  Hepatocyte-Derived Extracellular Vesicles Promote Endothelial Inflammation and Atherogenesis via microRNA-1. , 2020, Journal of hepatology.

[4]  J. Wolfram,et al.  Extracellular vesicle-based drug delivery systems for cancer treatment , 2019, Theranostics.

[5]  T. Berney,et al.  Assessment of plasma microvesicles to monitor pancreatic islet graft dysfunction: Beta cell‐ and leukocyte‐derived microvesicles as specific features in a pilot longitudinal study , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  Hélder A Santos,et al.  Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy , 2019, Nature Communications.

[7]  V. Mazzaferro,et al.  Heterologous and cross-species tropism of cancer-derived extracellular vesicles , 2019, Theranostics.

[8]  G. Raposo,et al.  Extracellular vesicles: a new communication paradigm? , 2019, Nature Reviews Molecular Cell Biology.

[9]  B. Baradaran,et al.  Liposome and immune system interplay: Challenges and potentials. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Haiyang Hu,et al.  Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. , 2019, Journal of materials chemistry. B.

[11]  Jie He,et al.  Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition) , 2019, Journal of Hematology & Oncology.

[12]  C. Su,et al.  Design strategies and application progress of therapeutic exosomes , 2019, Theranostics.

[13]  V. Mazzaferro,et al.  Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Mitchell S. Fourman,et al.  Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography Results in Negative Surgical Margins and Decreased Local Recurrence in an Orthotopic Mouse Model of Osteosarcoma , 2018, Annals of Surgical Oncology.

[15]  Jing Xu,et al.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.

[16]  A. Mäkitie,et al.  Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[17]  C. Garnis,et al.  The Role of Extracellular Vesicles in Cancer: Cargo, Function, and Therapeutic Implications , 2018, Cells.

[18]  Su Chul Jang,et al.  Subpopulations of extracellular vesicles and their therapeutic potential. , 2018, Molecular aspects of medicine.

[19]  Graça Raposo,et al.  Shedding light on the cell biology of extracellular vesicles , 2018, Nature Reviews Molecular Cell Biology.

[20]  Muller Fabbri,et al.  Biological roles and potential applications of immune cell-derived extracellular vesicles , 2017, Journal of extracellular vesicles.

[21]  Xin Luan,et al.  Engineering exosomes as refined biological nanoplatforms for drug delivery , 2017, Acta Pharmacologica Sinica.

[22]  Patrizia Agostinis,et al.  EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research , 2017, Nature Methods.

[23]  Xuetao Cao,et al.  Characteristics and Significance of the Pre-metastatic Niche. , 2016, Cancer cell.

[24]  Carla Oliveira,et al.  Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. , 2016, ACS nano.

[25]  Clotilde Théry,et al.  Communication by Extracellular Vesicles: Where We Are and Where We Need to Go , 2016, Cell.

[26]  Heikki Saari,et al.  Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[28]  L. O’Driscoll Expanding on exosomes and ectosomes in cancer. , 2015, The New England journal of medicine.

[29]  A. Molinari,et al.  Liposomes as nanomedical devices , 2015, International journal of nanomedicine.

[30]  Andrew F. Hill,et al.  Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper , 2015, Journal of extracellular vesicles.

[31]  L. O’Driscoll,et al.  Biological properties of extracellular vesicles and their physiological functions , 2015, Journal of extracellular vesicles.

[32]  Qiang Li,et al.  The Role of Indocyanine Green for Robotic Partial Nephrectomy: Early Results, Limitations and Future Directions , 2014, Robotics.

[33]  Hamid Cheshmi Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers , 2011 .

[34]  Takeaki Ishizawa,et al.  Real‐time identification of liver cancers by using indocyanine green fluorescent imaging , 2009, Cancer.

[35]  G. Parmiani,et al.  Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. , 2005, Gastroenterology.

[36]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[37]  J. Le Pecq,et al.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.

[38]  T. Whiteside,et al.  T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  Veronica Huber,et al.  Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles , 2002, The Journal of experimental medicine.

[40]  H. Stähelin Guidelines , 1994, Communicating Science.

[41]  Myung Soo Kim,et al.  Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[42]  Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. , 2016, Veterinary and comparative oncology.

[43]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[44]  Hongjun Gao,et al.  Nanoparticles for Biomedical Applications , 2007 .

[45]  R. C. Benson,et al.  SCIENTIFIC NOTE: Fluorescence properties of indocyanine green as related to angiography , 1978 .